



Reg. No. 31018  
Telephone: (203) 812-2712  
Date: 30 May 2007

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Tobias Wunberg, et al.

Group No.: not assigned

Serial No.: 10/579,253

Examiner: not assigned


Filed: 05/11/2006

For: Substituted Dihydroquinazolines II

**CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)**

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 30 May 2007

  
William F. Gray

**MAIL STOP AMENDMENT**  
**COMMISSIONER FOR PATENTS**  
**P.O. BOX 1450**  
**ALEXANDRIA, VA 22313-1450**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.


**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING**  
**INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed within three months of the filing or nationalization of this application, or before the mailing date of the first Office action on the merits.

**FEE PAYMENT**

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

  
William F. Gray  
Attorney for Applicant(s)  
Bayer Corporation  
400 Morgan Lane  
West Haven, CT 06516



## INFORMATION DISCLOSURE CITATION

Applicant(s)  
Tobias Wunberg, et al.

## U.S. PATENT DOCUMENTS

*		DOCUMENT NO.	DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

NAMES

		DOCUMENT NO.								DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION		
		20	04	4	1	7	9	0							YES	NO
TNT	F1	20	04	4	1	7	9	0	05/21/04	WO	Bayer Healthcare Ag.					
TNT	F2	20	04	7	2	0	4	8	08/26/04	WO	Bayer Healthcare Ag.					
TNT	F3	19	99	4	1	2	5	3	08/19/99	WO	Tularik Inc.					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

TNT	R1	Takao Saito, et al., "A Facile and Efficient Carbodiimide-Mediated Synthesis of Dihydroquinazolines via a Tandem Nucleophilic Addition-Intramolecular Hetero Conjugate Addition Annulation Strategy", TETRAHEDRON LETTERS, 1996, vol. 37 no. 2, pp. 209-212 .
TNT	R2	Fengjiang Wang, et al., "Solid-Phase Synthesis of 3,4-Dihydroquinazoline", TETRAHEDRON LETTERS, 1997, vol. 38 no. 50, pp. 8651-8654 .
TNT	R3	Yong Sup Lee, et al., "3,4-Dihydroquinazoline Derivatives as Novel Selective T-type Ca <sup>2+</sup> Channel Blockers", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, vol. 14, pp. 3379-3384 .

EXAMINER	\Tamthom N. Truong\	DATE CONSIDERED	5-27-10
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			